Literature DB >> 7695338

Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.

E Rubinstein1, S Dautrey, R Farinoti, L St Julien, J Ramon, C Carbon.   

Abstract

The intestinal transepithelial elimination of sparfloxacin and fleroxacin was compared with that of ciprofloxacin in a rat model following a single parenteral administration of 25 mg of each of the antibiotics per kg of body weight. All three fluoroquinolones were eliminated through the small intestine. Ciprofloxacin was eliminated in the proximal jejunum at a rate of 1.97 +/- 0.70 micrograms/cm2, while the elimination rates of fleroxacin and sparfloxacin were 0.64 +/- 026 and 0.21 +/- 0.10 micrograms/cm2, respectively, over a 90-min collection period. In the ileum, the elimination rates of ciprofloxacin, fleroxacin, and sparfloxacin over the same period were 1.44 +/- 0.77, 1.00 +/- 0.33, and 0.41 +/- 0.26 micrograms/mc2, respectively. These data suggest that these fluoroquinolones undergo a transepithelial elimination process in the small intestine. This route of elimination may be important in the therapy of bacterial diarrhea.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695338      PMCID: PMC162492          DOI: 10.1128/AAC.39.1.99

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Male-to-female transmission of human immunodeficiency virus infection by oro-genital sex.

Authors:  V Puro; P Narciso; E Girardi; L Antonelli; M Zaccarelli; G Visco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

2.  The intestinal elimination of ciprofloxacin in the rat.

Authors:  E Rubinstein; L St Julien; J Ramon; S Dautrey; R Farinotti; J F Huneau; C Carbon
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

3.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

4.  Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

Authors:  W L Hayton; V Vlahov; N Bacracheva; I Viachki; R Portmann; G Muirhead; K Stoeckel; E Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Intestinal elimination of ciprofloxacin in rabbits.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus.

Authors:  Y X Furet; J Deshusses; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Splenic enlargement and Traube's space: how useful is percussion?

Authors:  A N Barkun; M Camus; T Meagher; L Green; L Coupal; J De Stempel; S A Grover
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

  7 in total
  10 in total

1.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

Authors:  H Stass; D Kubitza; J-G Möller; H Delesen
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

3.  Excretion of ciprofloxacin into the large bowel of the rabbit.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis.

Authors:  M Ludwig; C A Jantos; S Wolf; M Bergmann; K Failing; H G Schiefer; W Weidner
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

5.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Sparfloxacin secretion across Caco-2 cells involves a multidrug resistance-like mechanism.

Authors:  E Cormet; A M Barlier; J F Huneau; E Rubinstein; C Carbon; R Farinotti; D Tomé
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 7.  Quinolone use in the developing world: state of the art.

Authors:  T E Tupasi
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 8.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

9.  Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.

Authors:  E Cormet-Boyaka; J F Huneau; A Mordrelle; P N Boyaka; C Carbon; E Rubinstein; D Tomé
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves.

Authors:  Ashenafi Feyisa Beyi; Jonathan P Mochel; Géraldine Magnin; Tyler Hawbecker; Clare Slagel; Grant Dewell; Renee Dewell; Orhan Sahin; Johann F Coetzee; Qijing Zhang; Paul J Plummer
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.